ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
Tag: HEB
Tuesday’s Small Cap Biopharma Catalyst Trade List
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
